Skip to main content
. 2017 Jun 20;26(18):3495–3507. doi: 10.1093/hmg/ddx235

Figure 7.

Figure 7

Heterozygosity for ARMC5 deficiency in mice and humans alters the PKA pathway. (A) Sf1 expression is significantly decreased in Armc5+/− adrenals at 12 months only. (B) Prkaca expression is significantly decreased in Armc5+/− adrenals; Prkar1a, Prkar1b, Prkar2b, Prkacb and Prkaca expression was analyzed by RTqPCR on mRNA from 12 and 18 months old Armc5+/+ and Armc5+/− adrenals. Bars represent the induction fold quantification at least six individual adrenals ± standard deviation. P-value was calculated using Student’s t-test. (C) Cα protein accumulation is decreased in Armc5+/− adrenals at 12 months and increased at 18 months. Western blot analysis was done on at least six adrenals per genotype. (D) Western blot quantification. (E) PKA activity is increased in Armc5+/− adrenals at basal condition at 18 months. Bars represent the mean PKA activity on at least six individual adrenals ± standard deviation. P-value was calculated using Student’s t-test. (F) Cα expression is decreased in the nodules of human patients with PMAH carrying ARMC5 mutations. Western blot analysis of Cα, R1α and GAPDH expression on PMAH with and without ARMC5 mutations. Bars represent the mean in at least four individuals per conditions ± standard deviation. (G) PKA activity is decreased in nodules with ARMC5 mutations in basal conditions only. Bars represent the mean PKA activity on at least four individual adrenals ± standard deviation. P-value was calculated using Student’s t-test.